Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALMB-0168 in Bone Metastatic Solid Tumors
NCT06416358Phase 2Not yet recruiting
- Sponsor
- AlaMab Therapeutics
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ALMB-0168 in breast cancer, prostate cancer (PCa), sponsored by AlaMab Therapeutics. Planned start May 2024; status: not yet recruiting.
02
Drugs
ALMB-0168
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT06416358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416358.